Long-term cognitive impairment and learning disabilities are a major public health concern that affects more than half of infants born very preterm with immature lung injury. Such infants have a global delay in cerebral maturation of gray and white matter structures, likely caused by high susceptibility to hypoxia-induced oxidative stress during this critical period. This stress can result in mitochondrial dysfunction. If mitochondrial-dependent oxidative metabolism is required for immature progenitor cells to mature, then mitochondrial dysfunction can result in failure of timely progenitor cell maturation. Little is known about the metabolic alterations or the dependence of neural progenitor cell maturation on mitochondrial metabolism in the developing brain. Our work will fill this gap in knowledge. We use a rodent model of chronic hypoxia to recapitulate the immature lung injury commonly found in very preterm infants, which causes global gray and white matter cellular dysmaturity and associated ultrastructural and behavioral deficits. In this study, we will investigate the metabolic effects of hypoxia on hippocampal dysmaturation and determine the developmental outcome of mitochondrial disruption. Our preliminary data on the hippocampus indicate that: i) hypoxia causes long-term decreases in biochemical markers of mitochondrial function; ii) hypoxia impairs expression of pyruvate dehydrogenase E1? independent of its inhibitors; and iii) conditional removal of pyruvate dehydrogenase E1? from GFAP-expressing radial glia stem cells prevents their maturation. A potential target for promoting recovery after perinatal brain injury is timely restoration of mitochondrial function and oxidative metabolism. Our published and preliminary data strongly suggest the novel findings that intranasal heparin-binding epidermal growth factor [HB-EGF] treatment after hypoxia may reverse hypoxia-induced cellular dysmaturation, restore mitochondrially produced N-acetyl aspartate, and ameliorate neurobehavioral deficits by targeting the mitochondria. We hypothesize that mitochondrial dysfunction results in delayed development of hippocampal neural progenitor cell capacity to perform oxidative energy metabolism, thus preventing their maturation. We will test the hypothesis that restoring mitochondrial function will enable these cells to meet their bioenergetic demands, permitting timely cellular maturation and recovery of function in the hippocampus. These hypotheses will be tested in three specific aims.
In Aim 1, we will determine whether hypoxia impairs mitochondrial function in the hippocampus.
In Aim 2, we will determine whether hypoxia or cell-specific removal of pyruvate dehydrogenase E1? in hippocampal neural progenitor cells delays differentiation and hippocampal behavioral deficits.
In Aim 3, we will determine whether intranasal HB-EGF treatment after hypoxia enhances mitochondrial function. Successful completion of these aims will elucidate a fundamental biochemical mechanism that determines differentiation failure of neural progenitor cells after hypoxia-induced injury and define a novel metabolic mechanism by which HB-EGF facilitates cellular and functional recovery after neonatal brain injury.
The proposed research is relevant to public health because more than half of the children born premature suffer from life-long neurodevelopmental delays that affect learning and cognition. This study will investigate in an animal model of preterm brain injury whether these delays are due to impaired brain energy metabolism, which is essential for growth and maturation during brain development. We will determine whether growth factor treatment reverses deficits by restoring brain energy metabolism.
| Scafidi, Joseph; Ritter, Jonathan; Talbot, Brooke M et al. (2018) Age-Dependent Cellular and Behavioral Deficits Induced by Molecularly Targeted Drugs Are Reversible. Cancer Res 78:2081-2095 |
